Volatile Analysis Corporation wins Qualifying Therapeutic Discovery Project grant for sorptive nasal stent technology

HUNTSVILLE, Alabama - November 5, 2010 - Volatile Analysis Corporation announced today the reception of a $206,000.00 Qualifying Therapeutic Discovery Project (QTDP) grant. Funded by the United States government (IRS, HHS, NIH), grants were awarded based on project merit to create and sustain high-quality, high-paying U.S. jobs that advance competitiveness in life, biological and medical sciences.

The grant acknowledges Volatile Analysis' work with patent pending sorptive nasal stent technology in disease and chemical detection The grant will aid in further development of a device that facilitates biomarker detection indicative of disease states. The patent pending sorptive nasal stent extracts trace levels of volatile and semi-volatile metabolites produced in the body that are indicative of disease states with potential for early detection of cancer and infectious diseases. Primary inventor Dr. Russell Bazemore said, "Volatile Analysis' sorptive nasal stent will work with standard gas chromatography thereby making the field of breath metabolomics available to a greater number of researchers. This will also enable a greater number of therapies to be screened."

This grant also provides an excellent opportunity for Volatile Analysis to expand its metabolomics presence and research efforts. Our interests in personalized medicine and advancements in human breath analysis for biomarkers and early detection of disease states will be a key driving factor in the development of non-invasive sampling media and extraction devices. Our parent company, Cocoon Resources, Inc., a management services and venture group supported this successful grant initiative and that relationship continues to bring additional resources for monetization of our technologies.

Click here to download pdf